Floatz logo

Fludarabine

Rhabdomyosarcoma

National Cancer Institute (NCI)Small moleculePhase 2Active
CCC
55/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
73/ 100

Competitive context

58 Active assets in the Rhabdomyosarcoma cohort.

Asset / SponsorPhaseRating
Ipilimumab
Children's National Research Institute
Phase 2BB
Eloxatin
National Cancer Institute (NCI)
Phase 2BB
Irinotecan
Milton S. Hershey Medical Center
Phase 2BB
CALCIUM PHOSPHATE
Children's Oncology Group
Phase 3BB
Cixutumumab
National Cancer Institute (NCI)
Phase 2B

View all 50 →

Same molecule, other indications

Fludarabine is also rated in:

acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →
Fanconi anemiaDormant
BBB
Indicative ·
76 / 100
View asset →
Recurrent Adult Diffuse Large Cell LymphomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →